Beta-adrenergic blockade in chronic heart failure.

M Bristow, J D Port
{"title":"Beta-adrenergic blockade in chronic heart failure.","authors":"M Bristow,&nbsp;J D Port","doi":"10.1080/140174398428045","DOIUrl":null,"url":null,"abstract":"<p><p>In summary, beta-blockade is currently the most promising \"new\" treatment undergoing Phase III testing in chronic heart failure. Multiple studies on the effects of these agents on LV function and chamber characteristics as well as limited survival data strongly suggest that these agents produce a beneficial effect on the natural history of heart failure. If this promise is borne out in the currently active or planned large-scale clinical trials, this form of therapy will emerge as the most valuable treatment available for chronic heart failure.</p>","PeriodicalId":79533,"journal":{"name":"Scandinavian cardiovascular journal. Supplement","volume":"47 ","pages":"45-55"},"PeriodicalIF":0.0000,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/140174398428045","citationCount":"40","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian cardiovascular journal. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/140174398428045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 40

Abstract

In summary, beta-blockade is currently the most promising "new" treatment undergoing Phase III testing in chronic heart failure. Multiple studies on the effects of these agents on LV function and chamber characteristics as well as limited survival data strongly suggest that these agents produce a beneficial effect on the natural history of heart failure. If this promise is borne out in the currently active or planned large-scale clinical trials, this form of therapy will emerge as the most valuable treatment available for chronic heart failure.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性心力衰竭的β -肾上腺素能阻断。
总之,β -阻断是目前在慢性心力衰竭中进行III期试验的最有希望的“新”治疗方法。关于这些药物对左室功能和心室特征影响的多项研究以及有限的生存数据强烈表明,这些药物对心力衰竭的自然史产生有益的影响。如果这一前景在目前正在进行的或计划中的大规模临床试验中得到证实,这种形式的治疗将成为慢性心力衰竭最有价值的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Abstracts of the XV Swedish Cardiovascular Spring Meeting. Göteborg, Sweden. April 17–19, 2013. Aortic regurgitation after transcatheter aortic valve implantation of the Edwards SAPIEN ™ valve. Preoperative NT-proBNP independently predicts outcome in patients with acute coronary syndrome undergoing CABG. Sildenafil after cardiac arrest and infarction; an experimental rat model. Similar survival 15 years after coronary artery surgery irrespective of left main stem stenosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1